Abstract: A light emitting display device includes a display panel including a first pixel group including a plurality of pixels in 2N rows. The light emitting display device further includes a second pixel group disposed subsequent to the first pixel group and including a plurality of pixels in 2N rows. The light emitting display device further includes an emission signal unit including a first emission stage for applying the same first emission signal to the first pixel group and a second emission stage for applying the same second emission signal to the second pixel group. In a first frame, a falling time of the first emission signal and a rising time of the second emission signal are different from each other.

Abstract: The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure, it is possible to produce an organic electroluminescent device having improved driving voltage, power efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: A picture generation apparatus and a control method thereof are disclosed. An embodiment of the present disclosure provides a picture generation apparatus including a light source; a Spatial Light Modulator (SLM) configured to output an image using light transmitted from the light source; and a control unit configured to control the light source and the SLM based on at least one of illuminance of the surroundings or content of the image.

Abstract: The present invention relates to a catalyst for hydrogenation of an aromatic compound, which is capable of greatly reducing the inactivation of a catalyst by using a support including a magnesium-based spinel structure, and a preparation method therefor.

Abstract: There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

Abstract: An apparatus and method for scheduling users in a mobile communication system are provided, in which a Base Station (BS) calculates scheduling utility values of each Mobile Station (MS) for a plurality of cases of interference from neighbor BSs, forms a candidate MS list by selecting a predetermined number of MSs in a descending order of utility value for each of the cases of interference from the neighbor BSs, transmits the candidate MS list to the neighbor BSs, receives candidate MS lists from the neighbor BSs, calculates the channel transmission rates of candidate MSs included in the candidate MS lists, and selects an MS to be serviced according to the channel transmission rates.

Abstract: Provided are an oxazole hydroxamic acid derivatives and pharmaceutically useful salt thereof as a histone deacetylase inhibitor. The oxazole hydroxamic acid derivative and pharmaceutically useful salt thereof, prepared in accordance with the present invention, can treat and/or prevent various cancers and inflammatory diseases caused by histone deacetylase.

Abstract: An apparatus and method for optimizing a data rate in a wireless communication system supporting Hybrid Automatic Repeat reQuest (HARQ) are provided. The method includes estimating Channel State Information (CSI) of a signal to be transmitted, by using other CSIs received in a previous cycle; determining an instantaneous data rate, at which the CSI is transmitted with an optimal data rate, and the amount of redundancy information to be retransmitted; and retransmitting the redundancy information of the signal according to the amount of redundancy information and the instantaneous data rate, if a receiving end requests signal retransmission. Accordingly, the packet can be transmitted with the optimal data rate.

Abstract: Provided is a pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder, comprising sodium phenylbutyrate (PBA). The pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder in accordance with the present invention provides effects capable of inhibiting increases in locomotor activity which is a behavioral indicator of drug or alcohol addiction or bipolar disorder, by controlling a level of a neurotransmitter via regulation of expression of a neurotransmitter transporter.

Abstract: Disclosed herein are isoxazole derivatives and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/?-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

Abstract: There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

Abstract: Provided is a pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder, comprising sodium phenylbutyrate (PBA). The pharmaceutical composition for prevention and treatment of drug or alcohol addiction or bipolar disorder in accordance with the present invention provides effects capable of inhibiting increases in locomotor activity which is a behavioral indicator of drug or alcohol addiction or bipolar disorder, by controlling a level of a neurotransmitter via regulation of expression of a neurotransmitter transporter.

Abstract: Provided are an oxazole hydroxamic acid derivative and a pharmaceutically useful salt thereof as a histone deacetylase inhibitor The oxazole hydroxamic acid derivative and pharmaceutically useful salt thereof, prepared in accordance with the present invention, can treat and/or prevent various cancers and inflammatory diseases caused by histone deacetylase.

Abstract: The present invention relates to a composition for diagnosing cancer metastasis comprising Ubiquitin C-terminal hydrolase-L1 (UCH-L1), a use of UCH-L1 for diagnosing cancer metastasis and a method for diagnosing cancer metastasis using the same; a composition for suppressing cancer metastasis comprising an inhibitor of UCH-L1, a use of an inhibitor of UCH-L1 for suppressing cancer metastasis and a method of suppressing cancer metastasis using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 protein, a use of UCH-L1 protein for screening a cancer metastasis inhibitor and a method of screening cancer metastasis inhibitor using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 gene, a use of UCH-L1 gene for screening a cancer metastasis inhibitor, a method of screening cancer metastasis inhibitor using the same. UCH-L1 is a key molecule to modulate cell migration including the cancer invasion according to their expressing level.

Abstract: Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/?-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

Abstract: An apparatus and method for scheduling users in a mobile communication system are provided, in which a Base Station (BS) calculates scheduling utility values of each Mobile Station (MS) for a plurality of cases of interference from neighbor BSs, forms a candidate MS list by selecting a predetermined number of MSs in a descending order of utility value for each of the cases of interference from the neighbor BSs, transmits the candidate MS list to the neighbor BSs, receives candidate MS lists from the neighbor BSs, calculates the channel transmission rates of candidate MSs included in the candidate MS lists, and selects an MS to be serviced according to the channel transmission rates.

Abstract: An apparatus and method for optimizing a data rate in a wireless communication system supporting Hybrid Automatic Repeat reQuest (HARQ) are provided. The method includes estimating Channel State Information (CSI) of a signal to be transmitted, by using other CSIs received in a previous cycle; determining an instantaneous data rate, at which the CSI is transmitted with an optimal data rate, and the amount of redundancy information to be retransmitted; and retransmitting the redundancy information of the signal according to the amount of redundancy information and the instantaneous data rate, if a receiving end requests signal retransmission. Accordingly, the packet can be transmitted with the optimal data rate.

Abstract: The present invention provides isolated nucleic acid constructs comprising a plant strong constitutive promoter operably linked to a heterologous nucleic acid which encodes a desired polypeptide in transgenic plant tissues. Said constructs are capable of conferring the highest expression of the desired polypeptides in plant root tissue and plant leaf tissue when used as a construct for a heterologous coding sequence in chimeric gene. After any chimeric gene can be linked to said construct, the resulting vector can be introduced into plant tissues, thereby intentionally modifying plants and making the resulting plants produce foreign substances therein.

Abstract: The present invention provides nucleotide and peptide sequences of an isolated cDNA coding for sunflower farnesyl pyrophosphate synthase, a key enzyme for the structurally diverse class of isoprenoid biosynthetic metabolites. The present invention also provides the recombinant plant expression vector comprising said nucleotide sequences and for the host cell into which said DNA sequence in the recombinant plant expression vector has been introduced to produce transgenic tobacco plants. Transgenic plants expressing heterologous farnesyl pyrophosphate synthase show 2-fold increase in seed production, higher chlorophyll contents in leaves as compared to non-transgenic or control vector-transformed tobacco plants. The expression vector for the sunflower farnesyl pyrophosphate synthase gene, herein designated pCIP-sfps, has been deposited with the Korea Research Institute of Bioscience and Biotechnology Korean Collection for Type Cultures (K.C.T.C.) designation number KCTC 0520BP, having been deposited on Sep.

Abstract: The present invention relates to a 9-hydroxypheophorbide-a derivative, pharmaceutically acceptable salt or acid addition salt used for photodynamic therapy represented by following formula (I) wherein R1 and R2 is each independently hydrogen, C1˜C6 linear or branched alkyl, or C3˜C8 aryl.